These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11943931)

  • 1. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
    Zangari M; Saghafifar F; Anaissie E; Badros A; Desikan R; Fassas A; Mehta P; Morris C; Toor A; Whitfield D; Siegel E; Barlogie B; Fink L; Tricot G
    Blood Coagul Fibrinolysis; 2002 Apr; 13(3):187-92. PubMed ID: 11943931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
    Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
    Zangari M; Anaissie E; Barlogie B; Badros A; Desikan R; Gopal AV; Morris C; Toor A; Siegel E; Fink L; Tricot G
    Blood; 2001 Sep; 98(5):1614-5. PubMed ID: 11520815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
    Zangari M; Barlogie B; Thertulien R; Jacobson J; Eddleman P; Fink L; Fassas A; Van Rhee F; Talamo G; Lee CK; Tricot G
    Clin Lymphoma; 2003 Jun; 4(1):32-5. PubMed ID: 12837152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
    Bradbury CA; Craig Z; Cook G; Pawlyn C; Cairns DA; Hockaday A; Paterson A; Jenner MW; Jones JR; Drayson MT; Owen RG; Kaiser MF; Gregory WM; Davies FE; Child JA; Morgan GJ; Jackson GH
    Blood; 2020 Aug; 136(9):1091-1104. PubMed ID: 32438407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
    Morgan GJ; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Cook G; Feyler S; Johnson PR; Rudin C; Drayson MT; Owen RG; Ross FM; Russell NH; Jackson GH; Child JA;
    Haematologica; 2012 Mar; 97(3):442-50. PubMed ID: 22058209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
    Badros A; Morris C; Zangari M; Barlogie B; Tricot G
    Leuk Lymphoma; 2002 Jun; 43(6):1267-71. PubMed ID: 12152995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
    Zangari M; Siegel E; Barlogie B; Anaissie E; Saghafifar F; Fassas A; Morris C; Fink L; Tricot G
    Blood; 2002 Aug; 100(4):1168-71. PubMed ID: 12149193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
    Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
    Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
    Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
    Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.
    Maiolino A; Hungria VT; Garnica M; Oliveira-Duarte G; Oliveira LC; Mercante DR; Miranda EC; Quero AA; Peres AL; Barros JC; Tanaka P; Magalhães RP; Rego EM; Lorand-Metze I; Lima CS; Renault IZ; Braggio E; Chiattone C; Nucci M; de Souza CA;
    Am J Hematol; 2012 Oct; 87(10):948-52. PubMed ID: 22730113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboembolic events during treatment with thalidomide.
    Urbauer E; Kaufmann H; Nösslinger T; Raderer M; Drach J
    Blood; 2002 Jun; 99(11):4247-8. PubMed ID: 12043695
    [No Abstract]   [Full Text] [Related]  

  • 13. Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.
    Kovacs MJ; Davies GA; Chapman JA; Bahlis N; Voralia M; Roy J; Kouroukis CT; Chen C; Belch A; Reece D; Zhu L; Meyer RM; Shepherd L; Stewart KA
    Br J Haematol; 2015 Feb; 168(4):511-7. PubMed ID: 25302852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities.
    Martinelli I; Battaglioli T; Bucciarelli P; Passamonti SM; Mannucci PM
    Circulation; 2004 Aug; 110(5):566-70. PubMed ID: 15262837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
    Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
    Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G
    J Clin Oncol; 2003 Jul; 21(14):2732-9. PubMed ID: 12860952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.
    Minnema MC; Breitkreutz I; Auwerda JJ; van der Holt B; Cremer FW; van Marion AM; Westveer PH; Sonneveld P; Goldschmidt H; Lokhorst HM
    Leukemia; 2004 Dec; 18(12):2044-6. PubMed ID: 15470485
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.